Oral delivery of semaglutide and tirzepatide using milk-derived small extracellular vesicles DOI Open Access
Yuefei Zhang, Jianmin Han, Wei Wu

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 29, 2024

Abstract Therapeutic proteins and peptides have revolutionized modern biomedicine. However, the large size complex structure of these macromolecules preclude their oral administration, greatly limiting applications in patient care. Biochemical degradation gastrointestinal tract, mucus, cellular barrier are major obstacles to development. Small extracellular vesicles (sEVs) natural nano lipid serving as essential vehicles for intercellular communication. sEVs resistant biochemical degradation, permeable mucus barriers, can penetrate barriers. thus considered next-generation with potential peptide/protein drug delivery. Herein, we report use milk-derived delivery achieve successful highly efficient two therapeutic GLP-1 receptor agonists, semaglutide tirzepatide. We showed that tirzepatide be efficiently loaded onto vitro, gavage semaglutide-loaded or tirzepatide-loaded effectively lower blood glucose levels db/db mouse models. This study demonstrates is a platform technology peptide opens new avenue therapeutics

Language: Английский

A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis DOI Creative Commons

Hannaneh Azimizonuzi,

Arman Ghayourvahdat,

Mareb Hamed Ahmed

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 27, 2025

Theranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) drugs safe and non-toxic; (2) they able to treat cancer selectively; (3) build up only cancerous tissue. Liposomes (LPs) are one most efficient drug delivery methods based on nanotechnology. Stealth LPs commercial have recently had an impact treatment. Using valuable information from each imaging technique, along multimodality functionality liposomal therapeutic agents, makes them very appealing personalized monitoring how well working against vivo predicting therapies will work. On other hand, their use as nanoparticle systems currently research development phase. Nanoscale system innovation has made LP-nanoparticle hybrid structures useful combining methods. LP-hybrid nanoparticles better at killing cells than LP counterparts, making excellent options vitro applications. Hybrid liposomes (HLs) could used future carriers find targets. This would combine features synthetic biological systems. Overarchingly, this article provided comprehensive overview many types detection, therapy, analysis. An evaluation pros cons HLs detection treatment also been conducted. The study included recent significant We conclude by outlining potential benefits drawbacks approach concurrent different malignancies, its prospects.

Language: Английский

Citations

7
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment DOI Creative Commons
Young‐Ju Jang,

Seong-Jun Kang,

Hyun Su Park

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 10, 2025

Alzheimer's disease (AD) is a distinctive form of dementia characterized by age-related cognitive decline and memory impairment. A key hallmark AD the irreversible overaccumulation beta-amyloid (Aβ) in brain, associated with neuroinflammation neuronal death. Although Aβ clearance immunoregulation have been major therapeutic strategies for AD, highly selective transport across blood–brain barrier (BBB) negatively affects delivery efficacy drugs without ability to cross BBB. In this review, we discuss potential lipid-based nanoparticles (LBNs) as promising vehicles drug treatment. LBNs, composed phospholipid mono- or bilayer, attracted attention due their exceptional cellular penetration capabilities loading capabilities, which also facilitate cargo transcytosis Recent advances development engineering LBNs overcome existing limitations current clinical approaches treatment addressing off-target effects low efficacy. Here, review pathways BBB, well various types therapy, including exosomes, liposomes, solid lipid (SLNs), nanostructured carriers (NLCs), elucidate properties, preparation methodologies, efficacy, thereby offering innovative avenues novel translation therapy.

Language: Английский

Citations

6
Surface Components and Biological Interactions of Extracellular Vesicles DOI
Jinping Wang, Kuoran Xing, Guoying Zhang

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Extracellular vesicles (EVs) are critical mediators of intercellular communication, carrying bioactive cargo and displaying diverse surface components that reflect their cellular origins functions. The EV surface, composed proteins, lipids, glycocalyx elements, plays a pivotal role in targeting recipient cells, mediating biological interactions, enabling selective delivery. This review comprehensively examined the molecular architecture surfaces, linking biogenesis to functional diversity, highlights therapeutic diagnostic potential diseases such as cancer cardiovascular disorders. Additionally, we explore emerging applications EVs, including machine-learning-assisted analysis, chemical integration, cross-system combinations. also discusses some key challenges clinical translation EV-related technologies.

Language: Английский

Citations

4
Leveraging nature’s nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications DOI Creative Commons
Yunxi Chen,

Noélie Douanne,

T.-C. Wu

et al.

Science Advances, Journal Year: 2025, Volume and Issue: 11(9)

Published: Feb. 26, 2025

Naturally occurring extracellular vesicles (EVs) and synthetic nanoparticles like liposomes have revolutionized precision diagnostics medicine. EVs excel in biocompatibility cell targeting, while offer enhanced drug loading capacity scalability. The clinical translation of is hindered by challenges including low yield heterogeneity, whereas face rapid immune clearance limited targeting efficiency. To bridge these gaps, biomimetic (SVs) emerged as innovative platforms, combining the advantageous properties liposomes. This review emphasizes critical aspects EV biology, such mechanisms EV-cell interaction source-dependent functionalities modulation, tissue regeneration, informing SV engineering. We reviewed a broad array SVs, with focus on lipid bilayered functionalized proteins. These include cell-derived nanovesicles, protein-functionalized liposomes, hybrid vesicles. By addressing current highlighting opportunities, this aims to advance SVs for transformative biomedical applications.

Language: Английский

Citations

4
Engineered Exosomes as Smart Drug Carriers: Overcoming Biological Barriers in CNS and Cancer Therapy DOI Creative Commons
Tanvi Premchandani, Amol Tatode, Jayshree Taksande

et al.

Drugs and Drug Candidates, Journal Year: 2025, Volume and Issue: 4(2), P. 19 - 19

Published: April 24, 2025

Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, the ability traverse physiological obstacles such blood–brain barrier (BBB) dense tumor stroma. Recent advances exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) cargo loading (siRNA, CRISPR-Cas systems, chemotherapeutics)—have enhanced their precision therapeutic utility. For CNS delivery, functionalized with brain-homing peptides RVG or TfR ligands) enabled efficient transport of neuroprotective agents gene-editing tools treat Alzheimer’s disease glioblastoma. In oncology, engineered loaded tumor-suppressive miRNAs immune checkpoint inhibitors exploit microenvironment (TME) features, acidity enzyme overexpression, spatially controlled release. Furthermore, hybrid exosome–liposome systems exosome–biomaterial composites are being explored improve payload capacity stability. Despite progress, challenges persist scalable production, batch consistency, regulatory standardization. This review critically evaluates engineering strategies, preclinical success, translational hurdles while proposing innovations AI-driven design patient-derived platforms personalized By bridging nanotechnology biomedicine, can represent a paradigm shift targeted offering safer more effective solutions historically intractable diseases.

Language: Английский

Citations

3
Latest advancements and trends in biomedical polymers for disease prevention, diagnosis, treatment, and clinical application DOI

Mingxia Jiang,

Huapan Fang, Huayu Tian

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 138 - 174

Published: Feb. 5, 2025

Language: Английский

Citations

2
Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake DOI

Yiyao Li,

H. Tian, Han Zeng

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: 672, P. 125319 - 125319

Published: Feb. 5, 2025

Language: Английский

Citations

2
Recent Advances in Degradable Biomedical Polymers for Prevention, Diagnosis and Treatment of Diseases DOI
Shuoxun Zhang, Huapan Fang, Huayu Tian

et al.

Biomacromolecules, Journal Year: 2024, Volume and Issue: 25(11), P. 7015 - 7057

Published: Oct. 18, 2024

Biomedical polymers play a key role in preventing, diagnosing, and treating diseases, showcasing wide range of applications. Their unique advantages, such as rich source, good biocompatibility, excellent modifiability, make them ideal biomaterials for drug delivery, biomedical imaging, tissue engineering. However, conventional suffer from poor degradation

Language: Английский

Citations

9
Modulating the elasticity of milk exosome-based hybrid vesicles to optimize transepithelial transport and enhance oral peptide delivery DOI

Peifu Xiao,

Haoyang Yuan, Hongbing Liu

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 36 - 51

Published: Feb. 4, 2025

Language: Английский

Citations

0
Needle-free injection devices for targeted oral delivery of macromolecules DOI

Zhonglin Fang,

Zhuohao Zhang, Luoran Shang

et al.

Science Bulletin, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0